FDA Information
Trimegestone is still under clinical development and has not yet received approval from the US FDA.
Regulatory authorities in Sweden recently approved the first commercial product using trimegestone, an HRT product, Totelle Sekvens®. Totelle® employs a cyclic regimen for hormone replacement with 14 days using 2 mg of 17 beta estradiol alone and 14 days in combination with 500 mcg of trimegestone. When Totelle Sekvens® is launched by Wyeth-Ayerst in Sweden later this year it will offer women effective relief from vasomotor symptoms associated with menopause, improved and predictable cycle control, and a better lipid profile in comparison to existing products.
Please visit the official site of the FDA for further information.
Why is this medication prescribed?
Dosage and using this medicine
What special precautions should I follow?
What should I do if I forget a dose?
What side effects can this medication cause?
What storage conditions are needed for this medicine?
In case of an emergency/overdose